Advertisement
Screener

SCHOLAR ROCK HOLDING CORPORATION (SRRK) Repayments of Debt

2.2 / 5 stars · 26/58 Roast Me

SCHOLAR ROCK HOLDING CORPORATION Repayments of Debt

SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Repayments of Debt of $365.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-09.

Discontinued › Cash Flow › Financing Activities

us-gaap:RepaymentsOfDebt · last filed 2021-03-09

  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for the quarter ending 2019-06-30 was $198.00K, a 19.28% increase year-over-year.
  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for the quarter ending 2019-03-31 was $167.00K, a 0.00% change year-over-year.
  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for fiscal 2019 was $365.00K, a 45.28% decline from fiscal 2018.
  • SCHOLAR ROCK HOLDING CORPORATION repayments of debt for fiscal 2018 was $667.00K.
Period endRepayments of Debt 3 monthRepayments of Debt 6 monthRepayments of Debt 9 monthRepayments of Debt 12 month
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09
$0.00
derived: sum of 2 quarters · filed 2021-03-09
$198.00K
derived: sum of 3 quarters · filed 2021-03-09
$365.00K
10-K · filed 2021-03-09
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$198.00K
derived: sum of 2 quarters · filed 2020-11-09
$365.00K
10-Q · filed 2020-11-09
$532.00K
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$198.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$365.00K
10-Q · filed 2020-08-07
$532.00K
derived: sum of 3 quarters · filed 2020-08-07
$699.00K
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$167.00K
10-Q · filed 2020-05-07
$334.00K
derived: sum of 2 quarters · filed 2020-05-07
$501.00K
derived: sum of 3 quarters · filed 2020-05-07
$667.00K
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$167.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$334.00K
derived: sum of 2 quarters · filed 2020-03-12
$500.00K
derived: sum of 3 quarters · filed 2020-03-12
$667.00K
10-K · filed 2020-03-12
2018-09-30$167.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$333.00K
derived: sum of 2 quarters · filed 2019-11-12
$500.00K
10-Q · filed 2019-11-12
2018-06-30$166.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
$333.00K
10-Q · filed 2019-08-14
2018-03-31$167.00K
10-Q · filed 2019-05-15
2017-09-30$167.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$500.00K
10-Q · filed 2018-11-08
2017-06-30$333.00K
10-Q · filed 2018-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
CG Oncology, Inc. (CGON)United States$6.095B-27.95
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29